Wanner, Christoph

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 237

Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline

Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members* (2014) · Annals of Internal Medicine

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 226

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 219

Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME Trial

Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 209

Advanced glycation end products and mortality in hemodialysis patients

Schwedler, S. B., Metzger, T., Schinzel, R., & Wanner, C. (2002) · Kidney International

Advanced Glycation End Products researchDialysis and Renal Disease Management

Cited by 195

Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD

Schneider, M. P., Raff, U., Kopp, C., Scheppach, J. B., Toncar, S., Wanner, C., Schlieper, G., Saritas, T., Floege, J., Schmid, M., et al. (2017) · Journal of the American Society of Nephrology

Sodium Intake and HealthBlood Pressure and Hypertension Studies

Cited by 195

Mediterranean diet as the diet of choice for patients with chronic kidney disease

Chauveau, P., Aparicio, M., Bellizzi, V., Campbell, K., Hong, X., Johansson, L., Kolko, A., Molina, P., Sezer, S., Wanner, C., et al. (2018) · Nephrology Dialysis Transplantation

Nutritional Studies and DietDialysis and Renal Disease Management

Cited by 165

Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA

McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 164

Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control

Inzucchi, S. E., Kosiborod, M., Fitchett, D., Wanner, C., Hehnke, U., Kaspers, S., George, J. T., & Zinman, B. (2018) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 162

Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics

Wanner, C., Krane, V., März, W., Olschewski, M., Asmus, H.-G., Krämer, W., Kühn, K.-W., Kütemeyer, H., Mann, J. F. E., Ruf, G., et al. (2004) · Kidney and Blood Pressure Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 157

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Zinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Fitchett, D., Kohler, S., Mattheus, M., Woerle, H. J., Broedl, U. C., Johansen, O. E., et al. (2017) · Stroke

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 136

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F. E., Shahinfar, S., Tuttle, K. R., Donner, J.-A., Jha, V., Nangaku, M., et al. (2020) · Kidney International

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 125

SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation

Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 123

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 120

Empagliflozin and major renal outcomes in heart failure

Packer, M., Butler, J., Zannad, F., Pocock, S. J., Filippatos, G., Ferreira, J. P., Brueckmann, M., Jamal, W., Zeller, C., Wanner, C., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 112

Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes

Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 110

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus

Jordan, J., Tank, J., Heusser, K., Heise, T., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., et al. (2017) · Journal of the American Society of Hypertension

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 102

Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry

Noordzij, M., Jager, K. J., van der Veer, S. N., Kramar, R., Collart, F., Heaf, J. G., Stojceva-Taneva, O., Leivestad, T., Buturovic-Ponikvar, J., Benítez Sánchez, M., et al. (2014) · Nephrology Dialysis Transplantation

Central Venous Catheters and HemodialysisDialysis and Renal Disease Management

Cited by 100

The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial

Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementObstructive Sleep Apnea Research

Cited by 93

Thyroid Function Within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis

Chaker, L., Baumgartner, C., den Elzen, W. P. J., Collet, T.-H., Ikram, M. A., Blum, M. R., Dehghan, A., Drechsler, C., Luben, R. N., Portegies, M. L. P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsAcute Ischemic Stroke Management

Cited by 92

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial

Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 85

Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients

Drechsler, C., Schneider, A., Gutjahr-Lengsfeld, L., Kroiss, M., Carrero, J. J., Krane, V., Allolio, B., Wanner, C., & Fassnacht, M. (2014) · American Journal of Kidney Diseases

Thyroid Disorders and TreatmentsDialysis and Renal Disease Management

Cited by 70

SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases

Wanner, C., & Marx, N. (2018) · Diabetologia

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 65

Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial

Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 62